This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1991 Mar;83(3):1115-7.

doi: 10.1161/01.cir.83.3.1115.

Adjuvant antiplatelet strategies in coronary thrombolysis

R C Becker, J M Gore

PMID: 1999021
DOI: 10.1161/01.cir.83.3.1115

Editorial

Adjuvant antiplatelet strategies in coronary thrombolysis

R C Becker et al. Circulation. 1991 Mar.

. 1991 Mar;83(3):1115-7.

doi: 10.1161/01.cir.83.3.1115.

Authors

R C Becker, J M Gore

PMID: 1999021
DOI: 10.1161/01.cir.83.3.1115

No abstract available

PubMed Disclaimer

Comment on

Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D. Yasuda T, et al. Circulation. 1991 Mar;83(3):1038-47. doi: 10.1161/01.cir.83.3.1038. Circulation. 1991. PMID: 1900221

Similar articles

Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Haskel EJ, et al. Circulation. 1991 Mar;83(3):1048-56. doi: 10.1161/01.cir.83.3.1048. Circulation. 1991. PMID: 1900222
Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, et al. Mousa SA, et al. Circulation. 1994 Jan;89(1):3-12. doi: 10.1161/01.cir.89.1.3. Circulation. 1994. PMID: 8281661
Principles underlying the use of conjunctive agents with plasminogen activators.
Shebuski RJ. Shebuski RJ. Ann N Y Acad Sci. 1992 Dec 4;667:382-94. doi: 10.1111/j.1749-6632.1992.tb51638.x. Ann N Y Acad Sci. 1992. PMID: 1309058 Review.
Dynamics of coronary thrombolysis and reocclusion.
Becker R. Becker R. Clin Cardiol. 1997 Nov;20(11 Suppl 3):III2-5. doi: 10.1002/clc.4960201403. Clin Cardiol. 1997. PMID: 9422855 Free PMC article.
Antiplatelet therapy--Part I.
Goodnight SH, Coull BM, McAnulty JH, Taylor LM. Goodnight SH, et al. West J Med. 1993 Apr;158(4):385-92. West J Med. 1993. PMID: 8317125 Free PMC article. Review.

See all similar articles

Cited by

Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
Lucchessi BR, Rote WE, Driscoll EM, Mu DX. Lucchessi BR, et al. Br J Pharmacol. 1994 Dec;113(4):1333-43. doi: 10.1111/j.1476-5381.1994.tb17144.x. Br J Pharmacol. 1994. PMID: 7889289 Free PMC article.
Aspirin for myocardial infarction. Clinical pharmacokinetic considerations.
Bochner F, Lloyd JV. Bochner F, et al. Clin Pharmacokinet. 1995 Jun;28(6):433-8. doi: 10.2165/00003088-199528060-00001. Clin Pharmacokinet. 1995. PMID: 7656501 Review. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information